Does Blue Cross Blue Shield of Minnesota Cover Eliquis?

What Is Eliquis and Why Do Insurers Scrutinize It?

Eliquis (apixaban) is a direct oral anticoagulant (DOAC) manufactured by Bristol-Myers Squibb and Pfizer. The FDA approved it in 2012 for stroke and systemic embolism prevention in nonvalvular atrial fibrillation, and again in 2012 and 2014 for DVT and PE treatment and prophylaxis [1]. Because it costs roughly ten to twenty times more than generic warfarin per month, commercial insurers including BCBS MN apply utilization management tools to control spend.

How Apixaban Works

Apixaban selectively inhibits free and clot-bound factor Xa, reducing thrombin generation without requiring routine INR monitoring [2]. The ARISTOTLE trial (N=18,201) showed apixaban reduced stroke or systemic embolism by 21% compared with warfarin (1.27% vs. 1.60% per year; P<0.001) and also cut major bleeding by 31% (2.13% vs. 3.09% per year; P<0.001) [3]. Those efficacy numbers are the clinical backbone of every prior authorization appeal you may need to write.

Why Insurers Place It on High Tiers

The list price of Eliquis exceeds $600 per 30-day supply at most US pharmacies [4]. Warfarin costs under $20 per month. Even rivaroxaban (Xarelto), another DOAC, sometimes receives preferential formulary status on specific BCBS MN plans because of negotiated rebates. Formulary placement is a business decision, not a clinical one, which is why your prescriber's documentation matters so much during the PA process.

BCBS Minnesota Formulary Basics

BCBS Minnesota administers multiple product lines: individual and family plans on and off the Minnesota exchange (MNsure), employer-sponsored group plans, and Medicare Advantage plans (including BlueCross Advantage and SecureBlue). Each product line maintains its own formulary, and Eliquis tier placement can differ across them.

Commercial Plan Tiers

On most BCBS MN commercial formularies, Eliquis sits at Tier 3 (preferred brand) or Tier 4 (non-preferred brand). A Tier 3 placement typically means a copay of $50, $100 per 30-day fill after the deductible is met. A Tier 4 placement can mean 30 to 50% coinsurance, which translates to $180, $300 out of pocket per fill when applying that percentage to the full retail price.

Generic apixaban became available at some US pharmacies following a 2023 patent settlement between Bristol-Myers Squibb and generic manufacturers [5]. Some BCBS MN formularies have begun placing generic apixaban on Tier 1 or Tier 2, which dramatically lowers cost-sharing. Call the Member Services number on the back of your insurance card or log in to the BCBS MN online drug lookup tool to check whether your specific plan lists the brand or generic, and at what tier.

Medicare Advantage Formularies

BCBS MN Medicare Advantage plans (Part D) follow CMS formulary rules. The 2024 CMS Part D guidance requires plans to include anticoagulants on formulary but does not mandate a specific tier [6]. On most BlueCross Advantage plans, Eliquis falls on Tier 3 (preferred brand) with a standard copay of $47 during the initial coverage phase as of the 2024 benefit year. During the coverage gap ("donut hole"), beneficiaries historically paid 25% of the plan's cost for brand drugs before catastrophic coverage kicked in. The Inflation Reduction Act of 2022 eliminated the coverage gap cost cliff for most beneficiaries beginning in 2025, capping annual Part D out-of-pocket costs at $2,000 [7].

MNsure Exchange Plans

MNsure silver and gold plans from BCBS MN generally include Eliquis on formulary with prior authorization. Cost-sharing varies by metal tier. Individuals with household incomes between 100% and 250% of the federal poverty level may qualify for cost-sharing reduction (CSR) subsidies that lower their effective copay. Checking formulary status at MNsure.org before enrollment is the cleanest way to compare options.

Prior Authorization Requirements for Eliquis Under BCBS MN

Prior authorization (PA) is the most common barrier to Eliquis access under BCBS MN. The plan requires your prescriber to submit clinical documentation before the pharmacy can dispense the drug at the insured rate.

What BCBS MN Typically Requires in a PA Request

Standard PA criteria for Eliquis at most commercial insurers, including BCBS MN, include the following points. The prescriber must document one of the FDA-approved indications: nonvalvular atrial fibrillation, DVT treatment, PE treatment, or postsurgical DVT/PE prophylaxis after hip or knee replacement [1]. The 2023 ACC/AHA/ACCP/HRS Atrial Fibrillation Guideline states directly: "In patients with AF and CHA2DS2-VASc score of 2 or greater in men or 3 or greater in women, oral anticoagulation is recommended, with DOACs (apixaban, dabigatran, edoxaban, or rivaroxaban) preferred over warfarin" [8]. Printing this exact recommendation as part of your PA submission strengthens the clinical rationale considerably.

Documentation of a CHA2DS2-VASc score of 2 or higher (for atrial fibrillation indications) is often required. Some plans additionally require documentation of renal function, since apixaban dosing adjustments are needed when two of three criteria are met: age 80 or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher [2].

Step Therapy: When Warfarin Trials Are Required

Certain BCBS MN group plans include a step therapy requirement. The insurer may ask your prescriber to document that warfarin was tried and either failed or is contraindicated before approving Eliquis. Minnesota state law (Minn. Stat. § 62Q.184) grants patients and prescribers rights to request a step therapy exception, and exceptions must be granted when the required first-step drug is contraindicated, has not been effective in the patient's prior experience, or is not in the patient's clinical interest based on medical or behavioral factors [9].

Conditions that commonly support a step therapy exception include labile INR on warfarin, patient inability to attend regular INR monitoring, specific drug interactions with warfarin (rifampin, certain antiepileptics), and clinician-documented preference for a DOAC based on bleeding risk profile assessed with tools such as HAS-BLED.

Turnaround Time and Urgent Requests

BCBS MN is required under Minnesota law to respond to standard PA requests within 3 business days and urgent PA requests within 24 hours. If a patient is hospitalized with a new diagnosis of atrial fibrillation or acute DVT/PE, the prescribing team should submit an urgent PA on day one of discharge planning to prevent coverage gaps.

How Much Will Eliquis Cost You With BCBS MN?

Cost depends on three factors: formulary tier, whether you have met your deductible, and whether you are using a copay assistance program.

Before Deductible Is Met

If your BCBS MN plan has a $1,500 or $3,000 deductible, you pay the full negotiated (contracted) rate for Eliquis until that deductible is satisfied. The contracted rate is typically $450, $540 for a 30-day brand supply, somewhat below the retail list price because of plan-level negotiation.

After Deductible Is Met

Once you have met the deductible, you pay your plan's tier copay or coinsurance. Tier 3 copays on BCBS MN commercial plans range from $50 to $110 per 30-day fill, based on publicly available summary of benefits documents. Tier 4 coinsurance of 30 to 50% on the contracted rate is meaningfully higher.

Eliquis 360 Support Copay Card

Bristol-Myers Squibb and Pfizer operate the Eliquis 360 Support program. Eligible commercially insured patients can reduce their monthly Eliquis copay to as low as $10, with a maximum annual savings of $6,400 [10]. Medicare beneficiaries do not qualify for manufacturer copay cards under federal anti-kickback rules, but they may qualify for the Eliquis Patient Assistance Program if income thresholds are met. The Extra Help (Low Income Subsidy) program administered by the Social Security Administration also reduces Part D cost-sharing significantly for qualifying Medicare beneficiaries [6].

Generic Apixaban Cost

Generic apixaban pricing varies by pharmacy and plan formulary. GoodRx-type pricing aggregators have listed generic apixaban at $30, $80 per 30-day supply at major chains, though actual BCBS MN contracted rates depend on negotiated pharmacy agreements. Ask your pharmacist to run both brand and generic pricing under your specific plan before filling.

What to Do If BCBS MN Denies Eliquis Coverage

Denial is not the end of the road. Roughly 40 to 50% of insurance denials are overturned on first-level internal appeal, based on data from CMS administrative review reports [6].

Step 1: Get the Denial in Writing

BCBS MN must provide a written denial explaining the specific criteria that were not met. Read that letter carefully. The denial code often tells you exactly what documentation to add.

Step 2: File an Internal Appeal

Your prescriber submits a peer-to-peer review request or written appeal with:

• The specific FDA indication and ICD-10 code (e.g., I48.0 for paroxysmal AF, I82.401 for acute DVT)
• The CHA2DS2-VASc score with component breakdown
• The ARISTOTLE trial citation demonstrating superior efficacy and lower major bleeding vs. Warfarin [3]
• Documentation of any contraindications or prior failures with the step-therapy drug
• The guideline language from the 2023 ACC/AHA/ACCP/HRS AF Guideline explicitly recommending DOACs [8]

The framework above (indication code plus CHA2DS2-VASc score plus trial data plus guideline language) is the four-part appeal structure the HealthRX clinical team uses when supporting patients through BCBS MN denials for Eliquis. It covers every criterion BCBS MN's standard PA criteria document asks reviewers to evaluate.

Step 3: External Review

If the internal appeal is denied, Minnesota residents have the right to an independent external review under Minn. Stat. § 62Q.73. The external reviewer is a third-party clinical organization with no financial relationship to BCBS MN. Requests must be filed within 60 days of the internal denial. External review decisions that favor the patient are binding on the insurer.

Step 4: Minnesota Commerce Department Complaint

If external review is unavailable or the timeline is creating a clinical emergency, filing a complaint with the Minnesota Department of Commerce (which regulates commercial health insurance) can accelerate resolution. The department's online complaint portal accepts cases involving coverage disputes.

Clinical Context: When Is Eliquis the Right Drug?

Understanding the clinical evidence helps patients and prescribers make the strongest possible case for coverage, and helps patients understand why their cardiologist or hematologist is recommending this specific agent.

Atrial Fibrillation Stroke Prevention

The ARISTOTLE trial remains the definitive evidence base for apixaban in AF. In 18,201 patients with AF and at least one additional risk factor, apixaban 5 mg twice daily reduced the primary endpoint of stroke or systemic embolism by 21% compared with dose-adjusted warfarin (hazard ratio 0.79; 95% CI 0.66 to 0.95; P<0.001 for noninferiority, P=0.01 for superiority) [3]. The reduction in hemorrhagic stroke was particularly marked, with a 49% relative risk reduction (0.24% vs. 0.47% per year) [3]. These numbers are meaningful in a PA appeal because they speak to why a DOAC is preferred over warfarin in most patients.

DVT and PE Treatment

The AMPLIFY trial (N=5,395) compared apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily with conventional therapy (enoxaparin followed by warfarin) for acute VTE. Apixaban was noninferior for the primary efficacy endpoint and produced 69% less major bleeding (0.6% vs. 1.8%; relative risk 0.31; 95% CI 0.17 to 0.55; P<0.001 for superiority on bleeding) [11]. This superior bleeding profile is directly relevant when making a case for Eliquis over warfarin during a step therapy appeal.

Postsurgical DVT Prophylaxis

The ADVANCE-2 trial (N=3,057) compared apixaban 2.5 mg twice daily with enoxaparin 40 mg once daily after total knee replacement. Apixaban produced a statistically significant reduction in the composite of DVT, nonfatal PE, and all-cause death (15.1% vs. 24.4%; P<0.0001) [12]. For patients requiring extended prophylaxis after total hip arthroplasty, the ADVANCE-3 trial (N=5,407) showed similar relative risk reductions with the 2.5 mg twice daily dose [13].

Renal Dosing Considerations

Apixaban requires dose reduction to 2.5 mg twice daily when at least two of the following three criteria are present: age 80 or older, body weight 60 kg or less, serum creatinine 1.5 mg/dL or higher [2]. For patients with end-stage renal disease on dialysis, the 2023 KDIGO guidelines acknowledge that apixaban may be used cautiously, but evidence is limited and warfarin remains an option in this population [14]. Documenting the correct dose and the reason for dose selection (with renal function labs) strengthens the PA submission.

Eliquis Alternatives Your BCBS MN Plan May Prefer

If BCBS MN's formulary places Eliquis at a high tier or subjects it to step therapy, your prescriber may consider alternatives. The clinical decision belongs to the prescriber, not the insurer, but understanding plan preferences helps.

Warfarin (Coumadin)

Generic warfarin costs under $15 per month and sits on Tier 1 of virtually every BCBS MN formulary. Its limitations include narrow therapeutic index, the need for routine INR monitoring, extensive drug and food interactions, and a higher rate of intracranial hemorrhage than DOACs [15]. The 2023 AF guideline explicitly states DOACs are preferred over warfarin for eligible patients [8].

Rivaroxaban (Xarelto)

Rivaroxaban (Xarelto) is another factor Xa inhibitor approved for similar indications. Some BCBS MN plans place rivaroxaban on a preferred tier relative to apixaban, depending on rebate negotiations. The ROCKET-AF trial (N=14,264) showed rivaroxaban was noninferior to warfarin for stroke prevention in AF (HR 0.88; 95% CI 0.74 to 1.03) but did not demonstrate superiority [16]. Prescribers who prefer apixaban over rivaroxaban on bleeding-risk grounds can reference the ARISTOTLE superiority data in a step-therapy exception request.

Dabigatran (Pradaxa)

Dabigatran (Pradaxa) is a direct thrombin inhibitor. The RE-LY trial (N=18,113) showed the 150 mg twice daily dose reduced stroke risk vs. Warfarin by 35% but was associated with a higher rate of major gastrointestinal bleeding [17]. Dabigatran requires dose adjustment for renal impairment and is contraindicated in patients with severe renal impairment (CrCl <15 mL/min) [17].

Generic Apixaban

As noted above, generic apixaban is now available in the US. If your plan's formulary lists the generic at a lower tier than brand Eliquis, generic apixaban is therapeutically equivalent and may substantially reduce your cost-sharing [5].

Practical Steps to Confirm Your Coverage Before Filling

Before sending your prescription to the pharmacy, take these concrete steps.

First, log in to your BCBS MN member account at bcbsmn.com and use the drug lookup tool with your specific plan ID. Search for both "apixaban" (generic) and "Eliquis" (brand) to see tier placement and PA requirements side by side.

Second, call Member Services (the number on the back of your card) and ask the representative specifically: Is a prior authorization required? Is step therapy required? What is the covered tier copay after my deductible? Is generic apixaban covered at a different tier?

Third, ask your prescriber to submit the PA before you go to the pharmacy. A pharmacy rejection on day one of discharge, or after a new diagnosis, can delay anticoagulation in a clinical situation where delay carries real stroke or thrombosis risk. The FDA's prescribing information for apixaban notes that discontinuing anticoagulation in the absence of adequate alternative anticoagulation increases stroke risk in AF patients [1].

Fourth, if cost remains a barrier after the PA is approved, apply for the Eliquis 360 Support copay card at Eliquis360support.com (commercial insurance only) or ask your prescriber about the manufacturer patient assistance program if you are uninsured or underinsured.

Minnesota-Specific Protections You Should Know

Minnesota has enacted several consumer protections that directly affect your rights when a plan denies Eliquis.

Step Therapy Exception Rights

Minn. Stat. § 62Q.184 requires commercial insurers to grant step therapy exceptions when the standard required drug is contraindicated, has not been effective in the past, or would adversely affect the member's health based on clinical evidence [9]. A prescriber who documents that warfarin produced labile INR (time in therapeutic range below 65%) or significant drug interactions in the past qualifies for this exception. The plan must respond to an exception request within 72 hours (or 24 hours if urgent).

External Review Rights

Under Minn. Stat. § 62Q.73, any member whose internal appeal is denied has the right to independent external review by a certified independent review organization. External review decisions are binding on the insurer and must be completed within 45 days (or 72 hours for urgent cases) [9].

Continuity of Care During Transitions

If a member is mid-course on Eliquis when switching BCBS MN plans (for example, during open enrollment), Minnesota continuity of care protections may require the new plan to cover the drug at the prior tier for a transition period. Confirming this protection with Member Services at the time of enrollment change is advisable.